ResultsIQ

ResultsIQ › Latest results › Anlon Healthcare Limited

Anlon Healthcare Limited Q1 FY27 results press release summary

NSE: AHCL · BSE: 544497

Results press release of 31 Jul 2026, summarised by AI from the filing.

Approximately 30% revenue CAGR over the next three years with EBITDA margins of 25%–30%.

Key takeaways

  1. Long-term guidance Approximately 30% revenue CAGR over the next three years with EBITDA margins of 25%–30%.
  2. Acquisition Acquired 63.98% stake in Remember India Health Links Pvt. Ltd. for ₹5.38 cr, completed 8 May 2026, making it a subsidiary.
  3. Forward-looking risk Forward-looking statements are subject to risks such as government actions, local developments and technological risks.

Original filing on BSE

Anlon Healthcare Limited Q1 FY27 results

As filed: Revenue ₹31.0 cr (−6% year on year), EBITDA ₹7.5 cr (+24% year on year), PAT ₹4.8 cr (+20% year on year), EBITDA margin 24.1% (+590 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹55.4 cr, EBITDA ₹13.9 cr, PAT ₹9.8 cr, EBITDA margin 25.1%. Not scored. No result for the same quarter last year. Share price after the results: +14.3% in 27 days (Nifty 500: +0.6%).
  • Q3 FY26: Revenue ₹35.6 cr, EBITDA ₹12.3 cr, PAT ₹5.2 cr, EBITDA margin 34.7%. Not scored. No result for the same quarter last year. Share price after the results: +0.9% in 30 days (Nifty 500: −6.9%).
  • Q2 FY26: Revenue ₹52.0 cr, EBITDA ₹13.0 cr, PAT ₹9.0 cr, EBITDA margin 25.0%. Not scored. No result for the same quarter last year. Share price after the results: −0.8% in 30 days (Nifty 500: −0.2%).
  • Q1 FY26: Revenue ₹33.0 cr, EBITDA ₹6.0 cr, PAT ₹4.0 cr, EBITDA margin 18.2%. Not scored. No result for the same quarter last year.

Past price moves after results do not indicate future moves. Not a recommendation.

Anlon Healthcare Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.